CG Oncology (CGON) Common Equity (2023 - 2026)
CG Oncology's (CGON) quarterly Common Equity came in at $1.1 billion in Q1 2026, up 54.92% YoY from $704.8 million in Q1 2025, and up 45.07% on a QoQ basis from $752.6 million in Q4 2025.
CG Oncology (CGON) Common Equity (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Common Equity data on file, last reported at $1.1 billion in Q1 2026.
- Quarterly Common Equity rose 54.92% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 54.92% YoY) and the FY2025 annual result came in at $752.6 million, up 2.62% from the prior year.
- Common Equity advanced to $1.1 billion in Q1 2026, from $752.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.1 billion in Q1 2026 to a low of -$123.1 million in Q4 2023.
- A 4-year average of $452.6 million and a median of $568.9 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity jumped 760.66% — and 2025, when it gained 2.62%.
- Tracing CGON's Common Equity over 4 years: stood at -$123.1 million in 2023, then soared by 695.76% to $733.4 million in 2024, then rose by 2.62% to $752.6 million in 2025, then soared by 45.07% to $1.1 billion in 2026.
- The last three Common Equity figures came in at $1.1 billion (Q1 2026), $752.6 million (Q4 2025), and $687.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 1.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 1.09 Bn |
| Dec 31, 2025 | 752.60 Mn |
| Sep 30, 2025 | 687.64 Mn |
| Jun 30, 2025 | 670.36 Mn |
| Mar 31, 2025 | 704.76 Mn |
| Dec 31, 2024 | 733.38 Mn |
| Sep 30, 2024 | 536.77 Mn |
| Jun 30, 2024 | 552.36 Mn |
| Mar 31, 2024 | 568.94 Mn |
| Dec 31, 2023 | -123.10 Mn |
| Sep 30, 2023 | -107.58 Mn |
| Jun 30, 2023 | -97.39 Mn |
| Mar 31, 2023 | -86.12 Mn |